151 filings
Page 5 of 8
8-K
g0dl7w7 839oq
14 Sep 18
Other Events
12:00am
8-K
ewyyly15wyxu5a bph71
4 Sep 18
Departure of Directors or Certain Officers
12:00am
8-K
8e1f sq3t4025451qb
17 Aug 18
Entry into a Material Definitive Agreement
4:01pm
8-K
erluoh4nmd06bug3os
7 Aug 18
Karyopharm Reports Second Quarter 2018 Financial Results and Highlights Recent Progress
7:18am
8-K
n5hz5jy
6 Aug 18
Other Events
4:17pm
8-K
6einqm0c45yxmmg8l
21 Jun 18
Submission of Matters to a Vote of Security Holders
4:02pm
8-K
7inot ydiz58sn4xs
20 Jun 18
Regulation FD Disclosure
7:01am
8-K
8tng9d k9fq
7 Jun 18
Regulation FD Disclosure
7:00am
8-K
otmg6p2rr1 ug
24 May 18
Entry into a Material Definitive Agreement
7:10am
8-K
2kf9nugdbp
10 May 18
Karyopharm Reports First Quarter 2018 Financial Results and Highlights Recent Progress
7:11am
8-K
6rfypeqx
3 May 18
Karyopharm Therapeutics Announces Pricing of Public Offering of Common Stock
5:02pm
8-K
5iu4mf7ycl8p55nh
1 May 18
Results of Operations and Financial Condition
4:20pm
8-K
u243r673
30 Apr 18
Other Events
4:12pm
8-K
z5v83llz05pqbd7kh3y
15 Mar 18
Karyopharm Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Recent Progress
12:00am
8-K
7xjuyql vklmcr
25 Jan 18
Departure of Directors or Certain Officers
12:00am
8-K
siknd3q44m20u
25 Jan 18
Karyopharm Announces Agreement for Biogen to AcquireKPT-350 for the Treatment of Neurological and Neurodegenerative Conditions
12:00am
8-K
wh05qyb
8 Jan 18
6th Annual J.P. Morgan Healthcare Conference January8-11, 2018
12:00am
8-K
axqq 6wpdax56
11 Dec 17
Karyopharm Presents Positive Selinexor Data from the Phase 1b/2 STOMP Study at the American
12:00am
8-K
sjsqkej9y
1 Dec 17
Entry into a Material Definitive Agreement
12:00am
8-K
6pqk4d1l1ai5a
2 Nov 17
Karyopharm Reports Third Quarter 2017 Financial Results and Highlights Recent Progress
12:00am